Top

Published in:

Open Access 09-03-2022 | Heart Failure

Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction

Authors: Yong Wang, Juan Zhang, Zhen Wang, Cheng Wang, Dufang Ma

Published in: Heart Failure Reviews | Issue 1/2023

Abstract

Although the prevalence of heart failure with preserved ejection fraction (HFpEF) is growing worldwide, its complex pathophysiology has yet to be fully elucidated, and multiple hypotheses have all failed to produce a viable target for therapeutic action or provide effective treatment. Cardiac remodeling has long been considered an important mechanism of HFpEF. Strong evidence has been reported over the past years that coronary microvascular dysfunction (CMD), manifesting as structural and functional abnormalities of coronary microvasculature, also contributes to the evolution of HFpEF. However, the mechanisms of CMD are still not well understood and need to be studied further. Coronary microvascular endothelial cells (CMECs) are one of the most abundant cell types in the heart by number and active players in cardiac physiology and pathology. CMECs are not only important cellular mediators of cardiac vascularization but also play an important role in disease pathophysiology by participating in the inception and progression of cardiac remodeling. CMECs are also actively involved in the pathogenesis of CMD. Numerous studies have confirmed that CMD is closely related to cardiac remodeling. ECs may serve a critical function in mediating the connection between CMD and HFpEF. It follows that CMECs participate in the mechanism of CMD leading to HFpEF. In this review article, we focus on the role of CMD in the pathogenesis of HFpEF resulting from cardiac remodeling and highlight the subsequent complexity of the EC-mediated correlation between CMD and HFpEF.

Tomasoni D, Adamo M, Lombardi CM, Metra M (2019) Highlights in heart failure. ESC Heart Fail 6(6):1105–1127. https://doi.org/10.1002/ehf2.12555CrossRef

Schwinger RHG (2021) Pathophysiology of heart failure. Cardiovasc Diagn Ther 11(1):263–276. https://doi.org/10.21037/cdt-20-302CrossRef

Oren O, Goldberg S (2017) Heart failure with preserved ejection fraction diagnosis and management. Am J Med 130(5):510–516CrossRef

Xanthopoulos A, Triposkiadis F, Starling RC (2018) Heart failure with preserved ejection fraction: classification based upon phenotype is essential for diagnosis and treatment. Trends Cardiovasc Med 28(6):392–400. https://doi.org/10.1016/j.tcm.2018.01.001CrossRef

Mohammed SF, Majure DT, Redfield MM (2016) Zooming in on the microvasculature in heart failure with preserved ejection fraction. Circ Heart Fail 9(7). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003272

Milicic D, Jakus N, Fabijanovic D (2018) Microcirculation and Heart Failure. Curr Pharm Des 24(25):2954–2959. https://doi.org/10.2174/1381612824666180625143232CrossRef

Kibel A, Selthofer-Relatic K, Drenjancevic I, Bacun T, Bosnjak I, Kibel D et al (2017) Coronary microvascular dysfunction in diabetes mellitus. J Int Med Res 45(6):1901–1929. https://doi.org/10.1177/0300060516675504CrossRef

Guarini G, Giuseppina Capozza P, Huqi A, Morrone D, M Chilian W, Marzilli M (2013) Microvascular function/dysfunction downstream a coronary stenosis. Curr Pharm Des 19(13):2366-74

Vancheri F, Longo G, Vancheri S, Henein M (2020) Coronary microvascular dysfunction. J Clin Med 9(9). https://doi.org/10.3390/jcm9092880

10.

Chen C, Wei J, AlBadri A, Zarrini P, Bairey Merz CN (2016) Coronary microvascular dysfunction- epidemiology, pathogenesis, prognosis, diagnosis, risk factors and therapy. Circ J 81(1):3–11. https://doi.org/10.1253/circj.CJ-16-1002CrossRef

11.

Camici PG, Tschope C, Di Carli MF, Rimoldi O, Van Linthout S (2020) Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res 116(4):806–816. https://doi.org/10.1093/cvr/cvaa023CrossRef

12.

Dryer K, Gajjar M, Narang N, Lee M, Paul J, Shah AP et al (2018) Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol 314(5):H1033–H1042. https://doi.org/10.1152/ajpheart.00680.2017CrossRef

13.

Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS et al (2018) Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 39(37):3439–3450. https://doi.org/10.1093/eurheartj/ehy531CrossRef

14.

Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT et al (2018) Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 39(10):840–849. https://doi.org/10.1093/eurheartj/ehx721CrossRef

15.

Xanthopoulos A, Dimos A, Giamouzis G, Bourazana A, Zagouras A, Papamichalis M et al (2020) Coexisting morbidities in heart failure: no robust interaction with the left ventricular ejection fraction. Curr Heart Fail Rep 17(4):133–144. https://doi.org/10.1007/s11897-020-00461-3CrossRef

16.

Wei J, Nelson MD, Sharif B, Shufelt C, Bairey Merz CN (2018) Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction: addressing knowledge gaps for evidence-based guidelines. Eur Heart J 39(37):3451–3453. https://doi.org/10.1093/eurheartj/ehy558CrossRef

17.

D’Amario D, Migliaro S, Borovac JA, Restivo A, Vergallo R, Galli M et al (2019) Microvascular dysfunction in heart failure with preserved ejection fraction. Front Physiol 10:1347. https://doi.org/10.3389/fphys.2019.01347CrossRef

18.

Liu BH, Li YG, Liu JX, Zhao XJ, Jia Q, Liu CL et al (2019) Assessing inflammation in Chinese subjects with subtypes of heart failure: an observational study of the Chinese PLA Hospital Heart Failure Registry. J Geriatr Cardiol 16(4):313–319. https://doi.org/10.11909/j.issn.1671-5411.2019.04.002CrossRef

19.

Hage C, Michaelsson E, Linde C, Donal E, Daubert JC, Gan LM et al (2017) Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: a holistic proteomic approach. Circ Cardiovasc Genet 10(1). https://doi.org/10.1161/CIRCGENETICS.116.001633

20.

Tona F, Serra R, Di Ascenzo L, Osto E, Scarda A, Fabris R et al (2014) Systemic inflammation is related to coronary microvascular dysfunction in obese patients without obstructive coronary disease. Nutr Metab Cardiovasc Dis 24(4):447–453. https://doi.org/10.1016/j.numecd.2013.09.021CrossRef

21.

van Heerebeek L, Paulus WJ (2016) Understanding heart failure with preserved ejection fraction: where are we today?. Neth Heart J 24(4):227–236. https://doi.org/10.1007/s12471-016-0810-1CrossRef

22.

Vasiljevic Z, Krljanac G, Zdravkovic M, Lasica R, Trifunovic D, Asanin M (2018) Coronary microcirculation in heart failure with preserved systolic function. Curr Pharm Des 24(25):2960–2966. https://doi.org/10.2174/1381612824666180711124131CrossRef

23.

Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J et al (2016) Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 18(7):744–758. https://doi.org/10.1002/ejhf.600CrossRef

24.

Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM et al (2011) Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the I-PRESERVE trial. Circ Heart Fail 4(3):324–331CrossRef

25.

Quercioli A, Pataky Z, Montecucco F, Carballo S, Thomas A, Staub C et al (2012) Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging 5(8):805–815. https://doi.org/10.1016/j.jcmg.2012.01.020CrossRef

26.

Campbell DJ, Somaratne JB, Prior DL, Yii M, Kenny JF, Newcomb AE et al (2013) Obesity is associated with lower coronary microvascular density. PLoS One 8(11):e81798. https://doi.org/10.1371/journal.pone.0081798CrossRef

27.

Jaiswal A, Nguyen VQ, Carry BJ, le Jemtel TH (2016) Pharmacologic and endovascular reversal of left ventricular remodeling. J Card Fail 22(10):829–839. https://doi.org/10.1016/j.cardfail.2016.03.017CrossRef

28.

Zhao W, Zhao J, Rong J (2020) Pharmacological modulation of cardiac remodeling after myocardial infarction. Oxid Med Cell Longev 2020:8815349. https://doi.org/10.1155/2020/8815349CrossRef

29.

Frangogiannis NG (2019) Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med 65:70–99. https://doi.org/10.1016/j.mam.2018.07.001CrossRef

30.

Li Y, Liang Y, Zhu Y, Zhang Y, Bei Y (2018) Noncoding RNAs in cardiac hypertrophy. J Cardiovasc Transl Res 11(6):439–449. https://doi.org/10.1007/s12265-018-9797-xCrossRef

31.

Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62(4):263–271. https://doi.org/10.1016/j.jacc.2013.02.092CrossRef

32.

Koller A, Szenasi A, Dornyei G, Kovacs N, Lelbach A, Kovacs I (2018) Coronary microvascular and cardiac dysfunction due to homocysteine pathometabolism; a complex therapeutic design. Curr Pharm Des 24(25):2911–2920. https://doi.org/10.2174/1381612824666180625125450CrossRef

33.

Kitabata H, Kubo T, Ishibashi K, Komukai K, Tanimoto T, Ino Y et al (2013) Prognostic value of microvascular resistance index immediately after primary percutaneous coronary intervention on left ventricular remodeling in patients with reperfused anterior acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 6(10):1046–1054. https://doi.org/10.1016/j.jcin.2013.05.014CrossRef

34.

Cheng R, Wei G, Yu L, Su Z, Wei L, Bai X et al (2014) Coronary flow reserve in the remote myocardium predicts left ventricular remodeling following acute myocardial infarction. Yonsei Med J 55(4):904–911. https://doi.org/10.3349/ymj.2014.55.4.904CrossRef

35.

Gulati A, Ismail TF, Ali A, Hsu LY, Goncalves C, Ismail NA et al (2019) Microvascular dysfunction in dilated cardiomyopathy: a quantitative stress perfusion cardiovascular magnetic resonance study. JACC Cardiovasc Imaging 12(8 Pt 2):1699–1708. https://doi.org/10.1016/j.jcmg.2018.10.032CrossRef

36.

Godo S, Suda A, Takahashi J, Yasuda S, Shimokawa H (2021) Coronary microvascular dysfunction. Arterioscler Thromb Vasc Biol 41(5):1625–1637. https://doi.org/10.1161/ATVBAHA.121.316025CrossRef

37.

Deng J (2021) Research progress on the molecular mechanism of coronary microvascular endothelial cell dysfunction. Int J Cardiol Heart Vasc 34:100777. https://doi.org/10.1016/j.ijcha.2021.100777CrossRef

38.

Crea F, Camici PG, Bairey Merz CN (2014) Coronary microvascular dysfunction: an update. Eur Heart J 35(17):1101–1111. https://doi.org/10.1093/eurheartj/eht513CrossRef

39.

Marinescu MA, Loffler AI, Ouellette M, Smith L, Kramer CM, Bourque JM (2015) Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC Cardiovasc Imaging 8(2):210–220. https://doi.org/10.1016/j.jcmg.2014.12.008CrossRef

40.

Lindemann H, Petrovic I, Hill S, Athanasiadis A, Mahrholdt H, Schaufele T et al (2018) Biopsy-confirmed endothelial cell activation in patients with coronary microvascular dysfunction. Coron Artery Dis 29(3):216–222. https://doi.org/10.1097/MCA.0000000000000599CrossRef

41.

Li Y, Zhang H, Liang Y, Wang W, Xu T, Zhang J et al (2018) Effects of hyperbaric oxygen on vascular endothelial function in patients with slow coronary flow. Cardiol J 25(1):106–112. https://doi.org/10.5603/CJ.a2017.0132CrossRef

42.

Ohura-Kajitani S, Shiroto T, Godo S, Ikumi Y, Ito A, Tanaka S et al (2020) Marked impairment of endothelium-dependent digital vasodilatations in patients with microvascular angina: evidence for systemic small artery disease. Arterioscler Thromb Vasc Biol 40(5):1400–1412. https://doi.org/10.1161/ATVBAHA.119.313704CrossRef

43.

Wang D, Luo P, Wang Y, Li W, Wang C, Sun D et al (2013) Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 62(5):1697–1708. https://doi.org/10.2337/db12-1025CrossRef

44.

He X, Zeng H, Chen ST, Roman RJ, Aschner JL, Didion S et al (2017) Endothelial specific SIRT3 deletion impairs glycolysis and angiogenesis and causes diastolic dysfunction. J Mol Cell Cardiol 112:104–113. https://doi.org/10.1016/j.yjmcc.2017.09.007CrossRef

45.

Lin J, Zhang L, Zhang M, Hu J, Wang T, Duan Y et al (2016) Mst1 inhibits CMECs autophagy and participates in the development of diabetic coronary microvascular dysfunction. Sci Rep 6:34199. https://doi.org/10.1038/srep34199CrossRef

46.

Segers VFM, Brutsaert DL, De Keulenaer GW (2018) Cardiac remodeling: endothelial cells have more to say than just NO. Front Physiol 9:382. https://doi.org/10.3389/fphys.2018.00382CrossRef

47.

Li Z, Zhang Y, Zhang Y, Yu L, Xiao B, Li T et al (2020) BRG1 Stimulates endothelial derived alarmin MRP8 to promote macrophage infiltration in an animal model of cardiac hypertrophy. Front Cell Dev Biol 8:569. https://doi.org/10.3389/fcell.2020.00569CrossRef

48.

Liu X, Wu J, Zhu C, Liu J, Chen X, Zhuang T et al (2020) Endothelial S1pr1 regulates pressure overload-induced cardiac remodelling through AKT-eNOS pathway. J Cell Mol Med 24(2):2013–2026. https://doi.org/10.1111/jcmm.14900CrossRef

49.

Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschope C et al (2016) Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 4(4):312–324. https://doi.org/10.1016/j.jchf.2015.10.007CrossRef

50.

Yu L, Yang G, Weng X, Liang P, Li L, Li J et al (2015) Histone methyltransferase SET1 mediates angiotensin II-induced endothelin-1 transcription and cardiac hypertrophy in mice. Arterioscler Thromb Vasc Biol 35(5):1207–1217. https://doi.org/10.1161/ATVBAHA.115.305230CrossRef

51.

Liu J, Zhuang T, Pi J, Chen X, Zhang Q, Li Y et al (2019) Endothelial Forkhead Box transcription factor P1 regulates pathological cardiac remodeling through transforming growth factor-beta1-endothelin-1 signal pathway. Circulation 140(8):665–680. https://doi.org/10.1161/CIRCULATIONAHA.119.039767CrossRef

52.

Adiarto S, Heiden S, Vignon-Zellweger N, Nakayama K, Yagi K, Yanagisawa M et al (2012) ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci 91(13–14):651–657. https://doi.org/10.1016/j.lfs.2012.02.006CrossRef

53.

Weng X, Yu L, Liang P, Chen D, Cheng X, Yang Y et al (2015) Endothelial MRTF-A mediates angiotensin II induced cardiac hypertrophy. J Mol Cell Cardiol 80:23–33. https://doi.org/10.1016/j.yjmcc.2014.11.009CrossRef

54.

Kivela R, Hemanthakumar KA, Vaparanta K, Robciuc M, Izumiya Y, Kidoya H et al (2019) Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-mediated paracrine signaling. Circulation 139(22):2570–2584. https://doi.org/10.1161/CIRCULATIONAHA.118.036099CrossRef

55.

Cheng W, Li X, Liu D, Cui C, Wang X (2021) Endothelial-to-mesenchymal transition: role in cardiac fibrosis. J Cardiovasc Pharmacol Ther 26(1):3–11. https://doi.org/10.1177/1074248420952233CrossRef

56.

Sun X, Nkennor B, Mastikhina O, Soon K, Nunes SS (2020) Endothelium-mediated contributions to fibrosis. Semin Cell Dev Biol 101:78–86. https://doi.org/10.1016/j.semcdb.2019.10.015CrossRef

57.

Gong H, Lyu X, Wang Q, Hu M, Zhang X (2017) Endothelial to mesenchymal transition in the cardiovascular system. Life Sci 184:95–102. https://doi.org/10.1016/j.lfs.2017.07.014CrossRef

58.

Chen PY, Schwartz MA, Simons M (2020) Endothelial-to-mesenchymal transition, vascular inflammation, and atherosclerosis. Front Cardiovasc Med 7:53. https://doi.org/10.3389/fcvm.2020.00053CrossRef

59.

S G, C C-V, F. S (2018) Transforming growth factor-beta family: advances in vascular function and signaling. Curr Protein Pept Sci 19(12):1164-71

60.

Xu L, Fu M, Chen D, Han W, Ostrowski MC, Grossfeld P et al (2019) Endothelial-specific deletion of Ets-1 attenuates angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition. BMB Rep 52(10):595–600. https://doi.org/10.5483/BMBRep.2019.52.10.206CrossRef

61.

Frias A, Lambies G, Vinas-Castells R, Martinez-Guillamon C, Dave N, Garcia de Herreros A et al (2015) A Switch in Akt isoforms is required for notch-induced snail1 expression and protection from cell death. Mol Cell Biol 36(6):923–940. https://doi.org/10.1128/MCB.01074-15CrossRef

62.

Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, Zeisberg EM (2015) Snail is a direct target of hypoxia-inducible factor 1alpha (HIF1alpha) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. J Biol Chem 290(27):16653–16664. https://doi.org/10.1074/jbc.M115.636944CrossRef

63.

Liu Y, Zou J, Li B, Wang Y, Wang D, Hao Y et al (2017) RUNX3 modulates hypoxia-induced endothelial-to-mesenchymal transition of human cardiac microvascular endothelial cells. Int J Mol Med 40(1):65–74. https://doi.org/10.3892/ijmm.2017.2998CrossRef

64.

Dhaun N, Webb DJ (2019) Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol 16(8):491–502. https://doi.org/10.1038/s41569-019-0176-3CrossRef

65.

Zhang X, Hu C, Yuan YP, Song P, Kong CY, Wu HM et al (2021) Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism. Cell Biol Toxicol. https://doi.org/10.1007/s10565-021-09581-5CrossRef

66.

Sandner P, Stasch JP (2017) Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Respir Med 122(Suppl 1):S1–S9. https://doi.org/10.1016/j.rmed.2016.08.022CrossRef

67.

Lee SW, Won JY, Kim WJ, Lee J, Kim KH, Youn SW et al (2013) Snail as a potential target molecule in cardiac fibrosis: paracrine action of endothelial cells on fibroblasts through snail and CTGF axis. Mol Ther 21(9):1767–1777. https://doi.org/10.1038/mt.2013.146CrossRef

68.

Yang RH, Tan X, Ge LJ, Sun JC, Peng XD, Wang WZ (2019) Interleukin enhancement binding factor 3 inhibits cardiac hypertrophy by targeting asymmetric dimethylarginine-nitric oxide. Nitric Oxide 93:44–52. https://doi.org/10.1016/j.niox.2019.09.002CrossRef

69.

Chan P, Liu JC, Lin LJ, Chen PY, Cheng TH, Lin JG et al (2011) Tanshinone IIA inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts. Am J Chin Med 39(2):381–394. https://doi.org/10.1142/S0192415X11008890CrossRef

70.

Gravning J, Ahmed MS, von Lueder TG, Edvardsen T, Attramadal H (2013) CCN2/CTGF attenuates myocardial hypertrophy and cardiac dysfunction upon chronic pressure-overload. Int J Cardiol 168(3):2049–2056. https://doi.org/10.1016/j.ijcard.2013.01.165CrossRef

71.

Qu H, Wang Y, Wang Y, Yang T, Feng Z, Qu Y et al (2017) Luhong formula inhibits myocardial fibrosis in a paracrine manner by activating the gp130/JAK2/STAT3 pathway in cardiomyocytes. J Ethnopharmacol 202:28–37. https://doi.org/10.1016/j.jep.2017.01.033CrossRef

72.

Tarbit E, Singh I, Peart JN, Rose’Meyer RB (2019) Biomarkers for the identification of cardiac fibroblast and myofibroblast cells. Heart Fail Rev 24(1):1–15. https://doi.org/10.1007/s10741-018-9720-1CrossRef

73.

Si L, Xu J, Yi C, Xu X, Wang F, Gu W et al (2014) Asiatic acid attenuates cardiac hypertrophy by blocking transforming growth factor-beta1-mediated hypertrophic signaling in vitro and in vivo. Int J Mol Med 34(2):499–506. https://doi.org/10.3892/ijmm.2014.1781CrossRef

74.

Zhang H, Hu J, Liu L (2017) MiR-200a modulates TGF-beta1-induced endothelial-to-mesenchymal shift via suppression of GRB2 in HAECs. Biomed Pharmacother 95:215–222. https://doi.org/10.1016/j.biopha.2017.07.104CrossRef

75.

Wei X, Yang Y, Jiang YJ, Lei JM, Guo JW, Xiao H (2018) Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway. Exp Ther Med 15(1):691–698. https://doi.org/10.3892/etm.2017.5448CrossRef

76.

Fan YH, Dong H, Pan Q, Cao YJ, Li H, Wang HC (2011) Notch signaling may negatively regulate neonatal rat cardiac fibroblast-myofibroblast transformation. Physiol Res 60(5):739–748. https://doi.org/10.33549/physiolres.932149CrossRef

77.

Zhou X, Chen X, Cai JJ, Chen LZ, Gong YS, Wang LX et al (2015) Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway. Drug Des Devel Ther 9:4599–4611. https://doi.org/10.2147/DDDT.S85399CrossRef

78.

Aquino-Galvez A, Gonzalez-Avila G, Jimenez-Sanchez LL, Maldonado-Martinez HA, Cisneros J, Toscano-Marquez F et al (2019) Dysregulated expression of hypoxia-inducible factors augments myofibroblasts differentiation in idiopathic pulmonary fibrosis. Respir Res 20(1):130. https://doi.org/10.1186/s12931-019-1100-4CrossRef

79.

Xu X, Tan X, Hulshoff MS, Wilhelmi T, Zeisberg M, Zeisberg EM (2016) Hypoxia-induced endothelial-mesenchymal transition is associated with RASAL1 promoter hypermethylation in human coronary endothelial cells. FEBS Lett 590(8):1222–1233. https://doi.org/10.1002/1873-3468.12158CrossRef

Title: Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction
Authors: Yong Wang
Juan Zhang
Zhen Wang
Cheng Wang
Dufang Ma
Publication date: 09-03-2022
Publisher: Springer US
Keyword: Heart Failure
Published in: Heart Failure Reviews / Issue 1/2023
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-022-10224-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure

Clinical application of CMR in cardiomyopathies: evolving concepts and techniques

Cardiac rehabilitation in heart failure with severely reduced ejection fraction: effects on mortality

Relationships among norepinephrine levels, exercise capacity, and chronotropic responses in heart failure patients

PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

Donor substance abuse and heart transplantation outcomes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page